WallStreetZenWallStreetZen

NASDAQ: VRNA
Verona Pharma PLC Stock Forecast, Predictions & Price Target

Analyst price target for VRNA

Based on 2 analysts offering 12 month price targets for Verona Pharma PLC.
Min Forecast
$32.00+75.92%
Avg Forecast
$32.50+78.67%
Max Forecast
$33.00+81.42%

Should I buy or sell VRNA stock?

Based on 2 analysts offering ratings for Verona Pharma PLC.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VRNA stock forecasts and price targets.

VRNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-01
lockedlocked$00.00+00.00%2024-01-22

1 of 1

Forecast return on equity

Is VRNA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.11%

Forecast return on assets

Is VRNA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

VRNA revenue forecast

What is VRNA's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$34.6M
Avg 2 year Forecast
$133.1M
Avg 3 year Forecast
$283.6M

VRNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRNA$18.19$32.50+78.67%Buy
FDMT$29.37$50.80+72.97%Strong Buy
ABCL$5.05$14.33+183.82%Strong Buy
XNCR$23.82$34.67+45.54%Buy
SLNO$49.19$55.60+13.03%Strong Buy

Verona Pharma Stock Forecast FAQ

Is Verona Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: VRNA) stock is to Buy VRNA stock.

Out of 2 analysts, 0 (0%) are recommending VRNA as a Strong Buy, 2 (100%) are recommending VRNA as a Buy, 0 (0%) are recommending VRNA as a Hold, 0 (0%) are recommending VRNA as a Sell, and 0 (0%) are recommending VRNA as a Strong Sell.

If you're new to stock investing, here's how to buy Verona Pharma stock.

What is VRNA's revenue growth forecast for 2024-2026?

(NASDAQ: VRNA) Verona Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.82%.

Verona Pharma's revenue in 2024 is $0.On average, 5 Wall Street analysts forecast VRNA's revenue for 2024 to be $22,390,452,345, with the lowest VRNA revenue forecast at $6,465,249,580, and the highest VRNA revenue forecast at $45,793,362,775. On average, 3 Wall Street analysts forecast VRNA's revenue for 2025 to be $86,056,351,060, with the lowest VRNA revenue forecast at $64,652,495,800, and the highest VRNA revenue forecast at $115,152,560,269.

In 2026, VRNA is forecast to generate $183,328,617,090 in revenue, with the lowest revenue forecast at $150,439,892,477 and the highest revenue forecast at $231,449,469,714.

What is VRNA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: VRNA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is VRNA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year VRNA price target, the average VRNA price target is $32.50, with the highest VRNA stock price forecast at $33.00 and the lowest VRNA stock price forecast at $32.00.

On average, Wall Street analysts predict that Verona Pharma's share price could reach $32.50 by Mar 1, 2025. The average Verona Pharma stock price prediction forecasts a potential upside of 78.67% from the current VRNA share price of $18.19.

What is VRNA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: VRNA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.